Comparative Pharmacology
Head-to-head clinical analysis: ENDEP versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDEP versus VIVACTIL.
ENDEP vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant